| 注册
首页|期刊导航|中国药房|我国医药监管机构体系存在的问题与重构建议

我国医药监管机构体系存在的问题与重构建议

鄢广

中国药房2016,Vol.27Issue(7):872-875,876,5.
中国药房2016,Vol.27Issue(7):872-875,876,5.DOI:10.6039/j.issn.1001-0408.2016.07.03

我国医药监管机构体系存在的问题与重构建议

Defects and Reconstruction Suggestion of Medical Regulatory System in China

鄢广1

作者信息

  • 1. 西南政法大学行政法学院,重庆 401120
  • 折叠

摘要

Abstract

OBJECTIVE:To provide reference for reconstructing medical regulatory system in China. METHODS:Through in-troducing medical regulatory setting mode in Britain and USA,combining the situation and problems of medical regulatory setting in China,and the assumption was put forward for medical regulatory system construction. RESULTS & CONCLUSIONS:Adher-ing to the principle of legalization,independence and speciality,Britain and USA set up various types medical regulatory in each professional field led by health departments. These medical regulatory institutions are charged with drug instrument regulation,medi-cal regulation monitoring,medical insurance monitoring,and other responsibilities. In China,medical regulatory function scatters in Food & Drug Administration,Health and Family Planning Department,Human Social Security Department,Price Department, etc.There are some problems which go against the relief of“difficulty and high cost of getting medical service”and“falsely high drug price”,such as low legalization,unclear regulatory function,poor independence and speciality. So,“super health”medical regulatory system,covering administration department,industry regulator institutions and professional technology institutions led by National Health and Family Planning Commission,should be established through grasping“super-ministries”reform opportunity and integrating medical regulatory function of Food & Drug Administration,Health and Family Planning Department,Human So-cial Security Department,by referring to Britain and USA experience.

关键词

医药监管机构/职能整合/大部制/构建

Key words

Medical regulatory/Function integration/Super-ministries/Construction

分类

医药卫生

引用本文复制引用

鄢广..我国医药监管机构体系存在的问题与重构建议[J].中国药房,2016,27(7):872-875,876,5.

中国药房

OA北大核心CSTPCD

1001-0408

访问量0
|
下载量0
段落导航相关论文